These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 29689693)

  • 1. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis.
    Jacobson W; Zhong W; Nomikos GG; Christensen MC; Kurre Olsen C; Harvey PD
    Curr Med Res Opin; 2020 Jan; 36(1):117-124. PubMed ID: 31422713
    [No Abstract]   [Full Text] [Related]  

  • 3. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings.
    Christensen MC; Sluth LB; McIntyre RS
    J Affect Disord; 2019 Feb; 245():508-516. PubMed ID: 30439678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
    Christensen MC; Munro V
    Curr Med Res Opin; 2018 Apr; 34(4):593-600. PubMed ID: 29235884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder.
    Harvey PD; Jacobson W; Zhong W; Nomikos GG; Cronquist Christensen M; Kurre Olsen C; Merikle E
    J Affect Disord; 2017 Apr; 213():105-111. PubMed ID: 28213121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
    Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
    Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
    Boulenger JP; Loft H; Olsen CK
    Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction.
    Keefe RSE; Nomikos G; Zhong W; Christensen MC; Jacobson W
    Int J Neuropsychopharmacol; 2018 May; 21(5):442-447. PubMed ID: 29546401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.
    Murthy NV; Xu R; Zhong W; Harvey PD
    J Affect Disord; 2020 Jan; 260():550-556. PubMed ID: 31539692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
    J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms.
    Xue L; Bocharova M; Young AH; Aarsland D
    J Affect Disord; 2024 Sep; 361():74-81. PubMed ID: 38838790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
    Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
    J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E; Sluth LB; Olsen CK
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.